New Results Provide Glimpse Into BlissBio's Enhertu Challenger In HER2-Low Breast Cancer

1 year ago 50

China's BlissBio has unveiled new clinical results for its HER2-targeting ADC BB-1701 in HER2-low breast cancer, which showed “promising” preliminary efficacy and "manageable" safety, in a glimpse into the Enhertu challenger's potential. 

1. Homepage
2. Breast Cancer
3. New Results Provide Glimpse Into BlissBio's Enhertu Challenger In HER2-Low Breast Cancer